C A Leissinger

Summary

Affiliation: Tulane University
Country: USA

Publications

  1. doi request reprint The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors
    Cindy A Leissinger
    Louisiana Center for Bleeding and Clotting Disorders, Tulane University Medical Center, New Orleans, Louisiana 70112, USA
    Am J Hematol 87:S23-6. 2012
  2. pmc Evidence of HIV exposure and transient seroreactivity in archived HIV-negative severe hemophiliac sera
    Scott A Tenenbaum
    Department of Biomedical Sciences, Ge NY Sis Center for Excellence in Cancer Genomics, University at Albany SUNY, Albany, NY, USA
    Virol J 2:65. 2005
  3. doi request reprint Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors
    Cindy Leissinger
    Louisiana Center for Bleeding and Clotting Disorders, Tulane University, New Orleans, LA, USA
    N Engl J Med 365:1684-92. 2011
  4. ncbi request reprint Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature
    Cindy A Leissinger
    The Louisiana Center for Bleeding and Clotting Disorders, Tulane University School of Medicine, New Orleans, Louisiana 70221 2699, USA
    Am J Hematol 83:137-43. 2008
  5. ncbi request reprint Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors
    C A Leissinger
    Section of Hematology Oncology, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Haemophilia 13:249-55. 2007
  6. ncbi request reprint Prophylaxis in haemophilia patients with inhibitors
    C A Leissinger
    Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
    Haemophilia 12:67-72; discussion 72-3. 2006
  7. ncbi request reprint Inhibitor development in patients with hemophilia: an overview
    Cindy A Leissinger
    Tulane University, New Orleans, LA 70112, USA
    Semin Hematol 43:S1-2. 2006
  8. ncbi request reprint Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction
    Cindy A Leissinger
    Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
    Am J Hematol 77:187-93. 2004
  9. ncbi request reprint Platelet kinetics in immune thrombocytopenic purpura and human immunodeficiency virus thrombocytopenia
    C A Leissinger
    Tulane University School of Medicine, Section of Hematology and Medical Oncology, New Orleans, Louisiana 70112 2699, USA
    Curr Opin Hematol 8:299-305. 2001
  10. ncbi request reprint Inhibitor development and successful immune tolerance in an HIV-infected patient with haemophilia A and after immune reconstitution with HAART
    R Kruse-Jarres
    Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Haemophilia 13:707-11. 2007

Research Grants

  1. Hemostasis Clinical Research Network Protocols
    Cindy Leissinger; Fiscal Year: 2007
  2. Hemostasis Clinical Research Network Protocols
    Cindy Leissinger; Fiscal Year: 2006

Detail Information

Publications14

  1. doi request reprint The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors
    Cindy A Leissinger
    Louisiana Center for Bleeding and Clotting Disorders, Tulane University Medical Center, New Orleans, Louisiana 70112, USA
    Am J Hematol 87:S23-6. 2012
    ..Over the last seven decades, major strides have been made in inhibitor treatment. This article focuses on the seminal clinical observations and studies that provided the foundation for these advances in hemophilia care...
  2. pmc Evidence of HIV exposure and transient seroreactivity in archived HIV-negative severe hemophiliac sera
    Scott A Tenenbaum
    Department of Biomedical Sciences, Ge NY Sis Center for Excellence in Cancer Genomics, University at Albany SUNY, Albany, NY, USA
    Virol J 2:65. 2005
    ....
  3. doi request reprint Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors
    Cindy Leissinger
    Louisiana Center for Bleeding and Clotting Disorders, Tulane University, New Orleans, LA, USA
    N Engl J Med 365:1684-92. 2011
    ..Effective strategies to prevent bleeding in such patients have not yet been established...
  4. ncbi request reprint Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature
    Cindy A Leissinger
    The Louisiana Center for Bleeding and Clotting Disorders, Tulane University School of Medicine, New Orleans, Louisiana 70221 2699, USA
    Am J Hematol 83:137-43. 2008
    ..Evidence-based treatment guidelines are needed to optimize the use of PCCs for warfarin reversal...
  5. ncbi request reprint Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors
    C A Leissinger
    Section of Hematology Oncology, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Haemophilia 13:249-55. 2007
    ..This case series demonstrates that routine aPCC administration may be used safely and effectively to reduce the occurrence of bleeding episodes and to maintain or improve clinical joint status in some patients...
  6. ncbi request reprint Prophylaxis in haemophilia patients with inhibitors
    C A Leissinger
    Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
    Haemophilia 12:67-72; discussion 72-3. 2006
    ..This article will review the published data on the use of bypassing agents in the prevention of bleeding, and will discuss ongoing clinical prophylaxis trials in inhibitor patients...
  7. ncbi request reprint Inhibitor development in patients with hemophilia: an overview
    Cindy A Leissinger
    Tulane University, New Orleans, LA 70112, USA
    Semin Hematol 43:S1-2. 2006
  8. ncbi request reprint Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction
    Cindy A Leissinger
    Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
    Am J Hematol 77:187-93. 2004
    ..However, only controlled clinical trials will ultimately demonstrate whether prophylaxis can prevent joint bleeding and damage, and improve quality of life in patients with inhibitors...
  9. ncbi request reprint Platelet kinetics in immune thrombocytopenic purpura and human immunodeficiency virus thrombocytopenia
    C A Leissinger
    Tulane University School of Medicine, Section of Hematology and Medical Oncology, New Orleans, Louisiana 70112 2699, USA
    Curr Opin Hematol 8:299-305. 2001
    ..For all patients with ITP-like disorders, these studies may also prove helpful in understanding and improving current therapies...
  10. ncbi request reprint Inhibitor development and successful immune tolerance in an HIV-infected patient with haemophilia A and after immune reconstitution with HAART
    R Kruse-Jarres
    Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Haemophilia 13:707-11. 2007
    ..Such a case serves to augment knowledge gained in animal studies about the immunobiology of FVIII inhibitors...
  11. ncbi request reprint Diabetes treatments have differential effects on nontraditional cardiovascular risk factors
    Vivian A Fonseca
    Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    J Diabetes Complications 20:14-20. 2006
    ..The aim of this study was to determine the effect of basal insulin, alone or with a sensitizer, or a combination of oral agents on nontraditional risk factors for cardiovascular disease (CVD)...
  12. doi request reprint Current management of acquired factor VIII inhibitors
    Brian Barnett
    Tulane University School of Medicine, New Orleans, Louisiana, USA
    Curr Opin Hematol 15:451-5. 2008
    ..Appropriate management requires the urgent treatment of bleeding episodes and prompt institution of immunosuppressive therapy for long-term inhibitor eradication...
  13. ncbi request reprint Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population
    S du Treil
    Tulane University Health Science Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Haemophilia 13:493-501. 2007
    ....
  14. ncbi request reprint Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B
    Bruce M Ewenstein
    Hematology Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Transfusion 42:190-7. 2002
    ..Hemophilia B is an X-linked bleeding disorder that affects approximately 1 in 25,000 males. Therapy for acute bleeding episodes consists of transfusions of plasma-derived (pd-F IX) or recombinant (r-F IX) concentrates...

Research Grants3

  1. Hemostasis Clinical Research Network Protocols
    Cindy Leissinger; Fiscal Year: 2007
    ..tulane university critiques ..
  2. Hemostasis Clinical Research Network Protocols
    Cindy Leissinger; Fiscal Year: 2006
    ..The second, short-term protocol, A prospective study of ribavirin for the treatment of HIVassociated immunopathic thrombocytopenic purpura (ITP), was developed to test a novel pharmacologic agent in the management of HIV-ITP. ..